Targeting SREBP-1-driven lipid metabolism to treat cancer

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2619-2626

  Guo, Deliang ^a   Bell, Erica Hlavin ^a   Mischel, Paul ^b   Chakravarti, Arnab ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

ABCA1; ACC; ACLY; FASN; LDLR; LXR; PI3K Akt; SREBP 1; SREBP 2; TCA cycle

Indexed keywords

ABC TRANSPORTER A1; ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ANTINEOPLASTIC AGENT; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; GLUTAMINE; LIPID; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; GLUTAMIC ACID;

AMINO ACID METABOLISM; ARTICLE; BIOENERGY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; FATTY ACID SYNTHESIS; GLIOBLASTOMA; GLUTAMINOLYSIS; GLYCOLYSIS; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANIMALS; CHOLESTEROL; GLUTAMIC ACID; GLYCOLYSIS; HUMANS; LIPID METABOLISM; LIPOGENESIS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LDL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84903703282     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990486     Document Type: Article

References (125)

1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews Cancer 2007; 7: 763-77.
2. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer research 1953; 13: 27-9.
3. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-8.
4. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. The New England journal of medicine 1989; 321: 636-41.
5. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380-4.
6. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481: 385-8.
7. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical cancer research: an official journal of the American Association for Cancer Research 2009; 15: 6479-83.
8. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
10. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Current opinion in cell biology 2010; 22: 422-9.
11. van Meer G. Lipids of the Golgi membrane. Trends in cell biology 1998; 8: 29-33.
12. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nature reviews Molecular cell biology 2008; 9: 112-24.
13. Maxfield FR. Plasma membrane microdomains. Current opinion in cell biology 2002; 14: 483-7.
14. Mukherjee S, Maxfield FR. Membrane domains. Annual review of cell and developmental biology 2004; 20: 839-66.
15. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr Relat Cancer 2010; 17: R287-304.
16. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005; 438: 612-21.
17. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nature reviews Cancer 2011; 11: 325-37.
18. Guo D, Prins RM, Dang J, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science signaling 2009; 2: ra82.
19. Guo D, Reinitz F, Youssef M, et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011; 1: 442-56.
20. Ettinger SL, Sobel R, Whitmore TG, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer research 2004; 64: 2212-21.
21. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
22. Bell EH, Guo D. Biomarkers for malignant gliomas. Malignant Gliomas, Radiation Medicine Rounds 2012; 3: 389-57.
23. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncology 2013; 2: 10.
24. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
25. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40.
26. Osborne TF, Espenshade PJ. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. Genes & development 2009; 23: 2578-91.
27. Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 2003; 278: 36652-60.
28. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 2003; 100: 12027-32.
29. Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends in endocrinology and metabolism: TEM 2011.
30. Yokoyama C, Wang X, Briggs MR, et al. SREBP-1, a basic-helixloop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993; 75: 187-97.
31. Motallebipour M, Enroth S, Punga T, et al. Novel genes in cell cycle control and lipid metabolism with dynamically regulated binding sites for sterol regulatory element-binding protein 1 and RNA polymerase II in HepG2 cells detected by chromatin immunoprecipitation with microarray detection. Febs J 2009; 276: 1878-90.
32. Nakakuki M, Shimano H, Inoue N, et al. A transcription factor of lipid synthesis, sterol regulatory element-binding protein (SREBP)-1a causes G(1) cell-cycle arrest after accumulation of cyclindependent kinase (cdk) inhibitors. Febs J 2007; 274: 4440-52.
33. Porstmann T, Griffiths B, Chung YL, et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24: 6465-81.
34. Yecies JL, Zhang HH, Menon S, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell metabolism 2011; 14: 21-32.
35. Sundqvist A, Ericsson J. Transcription-dependent degradation controls the stability of the SREBP family of transcription factors. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 13833-8.
36. Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Current opinion in cell biology 2007; 19: 215-22.
37. Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell metabolism 2005; 1: 379-91.
38. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell metabolism 2008; 8: 224-36.
39. Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146: 408-20.
40. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 3441-6.
41. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39: 171-83.
42. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
43. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
44. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
45. Hagiwara A, Cornu M, Cybulski N, et al. Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c. Cell metabolism 2012; 15: 725-38.
46. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
47. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
48. Babic I, Anderson ES, Tanaka K, et al. EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. Cell metabolism 2013; 17: 1000-8.
49. Katome T, Obata T, Matsushima R, et al. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. The Journal of biological chemistry 2003; 278: 28312-23.
50. Cong LN, Chen H, Li Y, et al. Physiological role of Akt in insulinstimulated translocation of GLUT4 in transfected rat adipose cells. Molecular endocrinology 1997; 11: 1881-90.
51. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. The Journal of experimental medicine 2011; 208: 313-26.
52. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature reviews Cancer 2011; 11: 85-95.
53. Menendez JA, Vellon L, Lupu R. Targeting fatty acid synthasedriven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 2005; 64: 997-1001.
54. Menendez JA, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 2005; 64: 342-9.
55. Hardwick DC. The fate of acetyl groups derived from glucose in the isolated perfused goat udder. Biochem J 1966; 99: 228-31.
56. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005; 24: 6314-22.
57. Ganguly J. Studies on the mechanism of fatty acid synthesis. VII. Biosynthesis of fatty acids from malonyl CoA. Biochim Biophys Acta 1960; 40: 110-8.
58. Gregolin C, Ryder E, Kleinschmidt AK, Warner RC, Lane MD. Molecular characteristics of liver acetyl CoA carboxylase. Proceedings of the National Academy of Sciences of the United States of America 1966; 56: 148-55.
59. Menendez JA, Lupu R, Colomer R. Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage? Mol Genet Metab 2005; 84: 293-5.
60. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076-80.
61. Wolf A, Agnihotri S, Munoz D, Guha A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiology of disease 2011; 44: 84-91.
62. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005; 18: 375-85.
63. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer research 2002; 62: 642-6.
64. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer research 2003; 63: 132-9.
65. Dang CV. Therapeutic Targeting of Myc-Reprogrammed Cancer Cell Metabolism. Cold Spring Harbor symposia on quantitative biology 2011.
66. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-50.
67. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 2010; 1: 734-40.
68. Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 19611-6.
69. Le A, Lane AN, Hamaker M, et al. Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. Cell metabolism 2012; 15: 110-21.
70. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The lancet oncology 2012.
71. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012.
72. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2: pe24.
73. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma--animal models and therapeutic challenges. Brain pathology 2009; 19: 112-20.
74. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011; 28: 334-40.
75. Atefi M, von Euw E, Attar N, et al. Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. PLoS One 2011; 6: e28973.
76. Niehr F, von Euw E, Attar N, et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of translational medicine 2011; 9: 76.
77. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.
78. Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer research 2004; 64: 31-4.
79. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 2011; 89: 205-12.
80. Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle 2010; 9: 211-2.
81. Guo D, Hildebrandt IJ, Prins RM, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 12932-7.
82. Abramson HN. The lipogenesis pathway as a cancer target. Journal of medicinal chemistry 2011; 54: 5615-38.
83. Yoon S, Lee MY, Park SW, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. The Journal of biological chemistry 2007; 282: 26122-31.
84. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-21.
85. Vazquez-Martin A, Colomer R, Brunet J, Menendez JA. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 2007; 31: 769-76.
86. Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother 2011; 65: 286-92.
87. Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer research 2007; 67: 8180-7.
88. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 3450-4.
89. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 2006; 7: 483-93.
90. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 2004; 41: 164-78.
91. Karantonis HC, Nomikos T, Demopoulos CA. Triacylglycerol metabolism. Curr Drug Targets 2009; 10: 302-19.
92. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV, Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. Journal of lipid research 2008; 49: 2283-301.
93. Lass A, Zimmermann R, Oberer M, Zechner R. Lipolysis-a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog Lipid Res 2011; 50: 14-27.
94. Krahmer N, Guo Y, Farese RV, Jr., Walther TC. SnapShot: Lipid Droplets. Cell 2009; 139: 1024-e1.
95. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140: 49-61.
96. Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. Journal of lipid research 2009; 50: 3-21.
97. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochemical Society transactions 2003; 31: 1120-4.
98. Holm C, Osterlund T, Laurell H, Contreras JA. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Annu Rev Nutr 2000; 20: 365-93.
99. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature medicine 2011; 17: 1498-503.
100. Coleman RA, Lewin TM, Van Horn CG, Gonzalez-Baro MR. Do long-chain acyl-CoA synthetases regulate fatty acid entry into synthetic versus degradative pathways? J Nutr 2002; 132: 2123-6.
101. Yamashita Y, Kumabe T, Cho YY, et al. Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas. Oncogene 2000; 19: 5919-25.
102. Mashima T, Oh-hara T, Sato S, et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. Journal of the National Cancer Institute 2005; 97: 765-77.
103. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
104. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-14.
105. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends in endocrinology and metabolism: TEM 2008; 19: 65-73.
106. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol 2010; 22: 422-9.
107. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42: 1346-67.
108. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-8.
109. Brown MS, Ho YK, Goldstein JL. The low-density lipoprotein pathway in human fibroblasts: relation between cell surface receptor binding and endocytosis of low-density lipoprotein. Ann N Y Acad Sci 1976; 275: 244-57.
110. Di Vizio D, Solomon KR, Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 2008; 94: 633-9.
111. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 1990; 50: 483-7.
112. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1513-8.
113. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9.
114. Chuu CP, Lin HP. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 2010; 30: 3643-8.
115. Mehrotra A, Kaul D, Joshi K. LXR-alpha selectively reprogrammes cancer cells to enter into apoptosis. Mol Cell Biochem 2011; 349: 41-55.
116. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes & development 2000; 14: 2831-8.
117. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325: 100-4.
118. Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell 2012; 148: 244-58.
119. Goldstein JL, Brown MS. From fatty streak to fatty liver: 33 years of joint publications in the JCI. J Clin Invest 2008; 118: 1220-2.
120. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009; 32: 1087-91.
121. Kones R. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis 2009; 3: 309-15.
122. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-42.
123. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008; 19: 113-21.
124. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 2008; 103: 2646-51.
125. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA: the journal of the American Medical Association 2006; 295: 74-80.